BTIG Research has recently reiterated Verastem Inc (VSTM) stock to Buy rating, as announced on December 31, 2024, according to Finviz. Earlier, on September 30, 2024, Guggenheim had initiated the ...

Verastem's promising therapy for LGSOC could position them as a commercial-stage company by 2025. Click here to find out why ...

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade ...

FDA officials have set a review date of June 30, 2025, to review avutometinib in combination with defactinib to treat ...

When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...

Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ...

The FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%.

Highlights,FDA grants Priority Review for new treatment combination in recurrent KRAS mutant LGSOC.,Phase 2 trial results ...

Under development at US pharma company Verastem Oncology (Nasdaq: VSTM), whose shares closed up 40.9% at $5.17 on Wednesday ...

Shares of Verastem surged after the company's new cancer treatment got priority review from regulators. The stock was up 46% at $5.37 on Tuesday. Shares are still down 35% since the start of the year.

The FDA granted priority review to the company's avutometinib-defactinib application and expects to decide on approval in June 2025.

Following news that the U.S. Food and Drug Administration approved its New Drug Application for avutometinib in combination ...